I'm pulling the OMIM entry for BMFS5 to confirm the variants and the cancer-risk detail. After that I'll write the report from the cached primary papers.

Bone Marrow Failure Syndrome 5 (BMFS5; germline TP53 C-terminal activation syndrome): research report

Source basis. Every claim below comes from the PubMed abstracts cached in references_cache/ (PMIDs 30146126, 30624728, 35084091, 35362179, 36198537, 37834388, 42104732), or from a web-search summary of the OMIM entry, which I labelled as a lead where I used it. Full texts were not read for the case reports, and the OMIM page itself failed to load (HTTP 420). Statements that rest only on model inference are marked [inferred]. Items I could not source are marked [gap]. Nothing here was checked against ClinVar, gnomAD, HPO annotations, or ClinicalTrials.gov.

1. Disease information

• Identifiers.
• MONDO:0032573, from the repo stub, with parent MONDO:0000159 (bone marrow failure syndrome).
• OMIM #618165, from the OMIM web-search summary (lead).
• Causal gene: TP53, hgnc:11998. The stub lists it as MONDO's causal gene.
• Orphanet, ICD-10/11, and MeSH IDs: [gap], not retrieved.
• Definition. An autosomal dominant inherited bone marrow failure syndrome (IBMFS). It is caused by de novo germline TP53 variants that truncate the C-terminal domain (CTD) and increase p53 transcriptional activity.
• Toki et al. (PMID:30146126, Am J Hum Genet 2018, primary, human genetics plus zebrafish and iPSC): "unique de novo TP53 germline variants found in two individuals with an IBMFS accompanied by hypogammaglobulinemia, growth retardation, and microcephaly mimicking DBA and DC."
• Ito (PMID:36198537, review) names it "germline TP53 activation syndrome (bone marrow failure syndrome 5)".
• Synonyms. Germline p53 activation syndrome (PMID:35362179). TP53-associated Diamond-Blackfan anemia / DBA-like phenotype (PMID:35084091, PMID:42104732).
• Lump/split call to surface. This is a germline entity. It is distinct from Li-Fraumeni syndrome (DNA-binding-domain loss of function, cancer predisposition) and from somatic TP53-mutant myeloid neoplasms (design decisions §3a). Whether the DBA-like cases should instead sit under Diamond-Blackfan anemia (RP-gene) as a subtype is a nosology question. DBA is defined by ribosomal-protein genes, and PMID:35084091 and PMID:42104732 frame these patients as "DBA-like" or "TP53-associated DBA". I would keep BMFS5 as its own entry and cross-reference DBA.
• Data level. The literature is aggregated case reports (n≈2 in the discovery paper, then a handful of further patients), not EHR-derived.

2. Etiology

• Cause. Heterozygous de novo germline TP53 frameshift variants clustered in the C-terminal domain.
• Toki: "the variants found in the two individuals studied here caused the same truncation of the protein, resulting in the loss of 32 residues from the C-terminal domain (CTD). Unexpectedly, the p53 mutant had augmented transcriptional activities, an observation not previously described in humans."
• Kumar et al. (PMID:35362179): third reported individual, "a germline heterozygous C-terminal frameshift variant in TP53 similar to others that activate the transcription factor."
• Moisan et al. (PMID:42104732, 2026): two French patients with NM_000546.5: c.1077delA; p.(Ser362AlafsTer8).
• Fedorova et al. (PMID:35084091): two patients with "germline de novo variants in the TP53 gene". The abstract gives no cDNA change.
• The Toki index-case nucleotide changes are [gap]. The shared outcome is a 32-residue CTD loss, which is consistent with the codon ~362 frameshift region. A ClinVar Miner search hit lists TP53 c.1083del p.Ser362fs, a lead that is not verified.
• Genetic risk factors. No modifier genes or susceptibility loci identified [gap].
• Environmental risk and protective factors; gene-environment interaction. None reported in the sources [gap].
• Related evidence on germline p53 hyperactivation. Rakotopare & Toledo (PMID:37834388, review): "germline mutations affecting TP53 or its regulator MDM4 may cause short telomeres and alter hematopoiesis, but also revealed features of Diamond-Blackfan anemia (DBA) or Fanconi anemia (FA)."

3. Phenotypes

Frequencies cannot be given because only about 6–8 patients are reported. HPO terms below are suggestions from my own recall and are unverified, so look each up before binding it.

• Variability.
• Steroid response differed across patients. One patient was steroid-responsive (PMID:35362179). Neither French patient responded (PMID:42104732).
• Anemia was normocytic in the French patients and macrocytic in the Russian ones.
• Neurological involvement varies.
• Quality-of-life data: none [gap].

4. Genetic and molecular information

• Gene. TP53, hgnc:11998, 17p13.
• Variant class. C-terminal frameshifts that remove the last 32 residues (PMID:30146126). This is a gain-of-function / hyperactivating effect on transcription, not the dominant-negative DNA-binding-domain effect typical of Li-Fraumeni. For the KB slot, functional_impact_category: GAIN_OF_FUNCTION fits, but check whether a finer value is warranted.
• Origin. De novo germline in all reported cases (PMID:30146126; PMID:35084091). Parental mosaicism and recurrence risk are [gap].
• Population frequency, ACMG classification, and ClinGen gene-disease validity: [gap]. A ClinGen assertion would be worth looking up in the CGGV: cache. I did not check it.
• Epigenetic and chromosomal findings: none reported.

5. Environmental information

None reported. A cellular radiosensitivity finding in one patient (PMID:35362179) is a cell-level observation, not an environmental risk factor. No infectious or lifestyle contributors are reported.

6. Mechanism and pathophysiology (causal chain)

1. De novo TP53 frameshift in the C-terminal domain deletes 32 residues (PMID:30146126, human genetics).
2. Loss of the CTD increases p53 transcriptional activity. Toki reports "the p53 mutant had augmented transcriptional activities" (in vitro). The CTD normally restrains DNA binding, so I infer the restraint is lost [inferred].
3. p53 hyperactivation leads to impaired erythropoiesis. Expression in zebrafish and human iPSCs gave "impaired erythrocyte production" (PMID:30146126, model organism and in vitro).
4. Impaired erythropoiesis results in early-onset red cell aplasia / anemia, a DBA-like picture.

5. Branch, non-hematologic. Constitutive p53 activity likely leads to growth failure, microcephaly, and hypogammaglobulinemia [inferred]. The supporting data are mouse knock-ins (see section 15) and the review PMID:30624728, which states "increased p53 activity underlies the developmental defects in a wide range of genetic syndromes."

6. Positive feedback context. In other BMFS, ribosomal, telomere, or DNA-repair defects activate p53, and p53-DREAM represses further BMFS-related genes (PMID:37834388, review, partly computational). BMFS5 is the reverse case, where p53 activation is primary and not a downstream consequence of another defect.

7. Suggested terms (verify).
8. GO: positive regulation of apoptotic process, GO:0043065; cell cycle arrest, GO:0007050; erythrocyte differentiation, GO:0030218.
9. CL: erythroid progenitor / hematopoietic stem cell.
10. Omics: no single-cell, proteomic, or metabolomic data found [gap].

7. Anatomical structures affected

• Bone marrow (UBERON:0002371), especially the erythroid lineage.
• Brain (microcephaly, seizures), by phenotype.
• Immune system (humoral).
• Growth axis.

Lateralization is not applicable.

8. Temporal development

• Onset. Infancy. Macrocytic anemia appeared within the first year in the Russian patients (PMID:35084091); the OMIM summary says infantile onset.
• Course and remission.
• Two patients became transfusion-independent "probably due to L-leucine therapy" (PMID:35084091).
• One patient was steroid-responsive (PMID:35362179).
• Long-term natural history [gap].
• Cancer risk. Whether CTD-truncating carriers have an elevated cancer risk is not addressed in the sources I read [gap]. This matters for surveillance counseling, because the usual Li-Fraumeni protocols may not apply to a hyperactivating allele.

9. Inheritance and population

• Autosomal dominant, all reported variants de novo (PMID:30146126; PMID:35084091).
• Prevalence, incidence, sex ratio, founder effects, and penetrance: [gap]. Fewer than ten patients across Japan, Russia, the USA, and France.

10. Diagnostics

• Laboratory. Anemia with erythroid hypoplasia on marrow examination, hypogammaglobulinemia, and normal telomere length, which argues against dyskeratosis congenita (PMID:35362179).
• Genetic testing. TP53 variants were found by exome sequencing in the discovery paper (Ito, PMID:36198537: "using whole-exome sequencing"). The practical point is that TP53 should be on DBA / IBMFS panels. PMID:35084091 states "The possible role of TP53 variants should be considered in patients with DBA-like phenotype and no mutations in RP genes."
• Differential diagnosis. DBA (RP genes), dyskeratosis congenita (telomere biology disorders), Fanconi anemia, Li-Fraumeni syndrome (different variant class).
• Guideline-level criteria, screening, and biomarkers: [gap].

11. Outcome and prognosis

• Survival and life expectancy: [gap].
• Complications: reported features include growth failure and neurodevelopmental impairment.
• Recovery. The French report documents the "only patient to date cured by hematopoietic stem cell transplantation" from a matched sibling donor, transfusion-independent at last follow-up (PMID:42104732).

12. Treatment (all from case-level observations)

• Transfusion support. Implied by the transfusion-dependent anemia in the OMIM summary (lead).
• Corticosteroids. Responsive in one patient (PMID:35362179). Non-responsive in the two French patients (PMID:42104732).
• L-leucine. Two patients became transfusion-independent, "probably due to L-leucine therapy" (PMID:35084091). This is uncontrolled and causality is uncertain.
• Hematopoietic stem cell transplantation. One patient cured by matched-sibling HSCT (PMID:42104732). A single case.
• NCIT. NCIT C15431 (hematopoietic cell transplantation) is already in the repo's CLAUDE.md. Other drug and supportive-care NCIT terms need a lookup. I did not run one.
• No clinical trials were checked [gap].

13. Prevention

Genetic counseling, with a de novo origin implying a low recurrence risk, except for germline mosaicism [inferred]. Everything else is [gap].

14. Other species and natural disease

No naturally occurring animal disease was identified [gap]; OMIA was not searched.

15. Model organisms

• Zebrafish and human iPSC. Mutant p53 expression impaired erythrocyte production (PMID:30146126).
• Mouse. Toki points to "close similarities to published knock-in mouse models of TP53 lacking the CTD." The mouse primary papers are not cited in the abstract and I did not retrieve them.
• Mouse p53 hyperactivation reviews. PMID:30624728 (Bowen & Attardi) reports that hematopoietic, neuronal, craniofacial, cardiovascular, and pigmentation defects arise in mice with broad p53 hyperactivation, and that many are rescued by p53 loss. This is a model-organism review and not a human phenotype source.
• Limitation. Whether mouse CTD-deletion phenotypes map one-to-one to human BMFS5 is open; a HUMAN_MODEL_MISMATCH discussion may be warranted if curated.

Notes for curation

1. The KB file is a stub-level placeholder. kb/disorders/Bone_Marrow_Failure_Syndrome_5.yaml currently has 8 lines, with only the name and disease_term. The seven reference-cache files are untracked.
2. Before writing evidence snippets, run just count-verified-snippets. All quotes above come from the cached abstracts and should be re-copied exactly from the cache.
3. Priority gaps. The Toki cDNA/protein nomenclature, ClinGen validity, cancer risk, and the mouse primary papers.

Sources

• PMID:30146126 – Toki et al., Am J Hum Genet 2018
• PMID:30624728 (Bowen & Attardi 2019), PMID:35084091 (Fedorova 2022), PMID:35362179 (Kumar 2022), PMID:36198537 (Ito 2022), PMID:37834388 (Rakotopare & Toledo 2023), PMID:42104732 (Moisan 2026), all from references_cache/
• OMIM #618165 mirror (not loaded; used via search summary only)
• Repo stub stubs/Bone_Marrow_Failure_Syndrome_5.yaml (MONDO:0032573, TP53)

Reference Validation

Checked with linkml-reference-validator 0.3.0.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

• GO:0007050 (GO_0007050) (1 mention) - replaced by GO:0051726

13 of 14 terms resolved to a current term; the rest could not be looked up either way.